Toregem BioPharma, a biotechnology firm based in Kyoto, Japan, has successfully raised approximately $5.3 million (¥850 million) in a Pre-Series C funding round to advance clinical trials for its innovative tooth-regeneration drug, TRG-035. This funding will facilitate Phase II trials in Japan and prepare for future developments in the United States. TRG-035 works by blocking the USAG-1 protein, which inhibits tooth growth, potentially allowing dormant tooth buds in the jaw to activate and regenerate teeth. The company aims to first target patients with congenital tooth agenesis, a condition characterized by the absence of permanent teeth. Although initial animal studies have shown promise, experts like Montse Timoneda emphasize the need for caution, noting that human trials are still in early stages and full results have yet to be published. While the therapy represents a significant advancement in dental medicine, it remains to be seen if it can effectively replace traditional dental implants in the future.